Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be highly variable between patients. To date, the approval of Benlysta in 2011 is the most notable development in the SLE market following the failure of several promising therapies to pass their Phase III programs. However, Benlysta’s modest efficacy is a major deterrent to its uptake. The unmet need remains high for effective SLE therapies, and several pharmaceutical companies are attempting to enter this market with multiple pending molecules. As these new SLE therapies seek to launch, the Disease Landscape and Forecast provides detailed analyses into current medical practice, key unmet needs, and new developments in the SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.

Questions answered:

  • How large is the treatable SLE population, and how will diagnosis / drug-treatment rates change over the 2018-2028 forecast period?
  • What is the current state of SLE treatment? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What are the key unmet needs in SLE?
  • Which novel therapies are most promising and what sales / uptake could they secure in SLE? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 16 country-specific interviews with rheumatologists and nephrologists.

Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).

Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.

Emerging therapies: Phase II: 16 drugs; Phase III: 5 drugs.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Systemic Lupus Erythematosus - Key Findings - August 2019
    • Key Updates
      • August 2019
      • May 2019
      • November 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Systemic Lupus Erythematosus?
        • What Factors Are Constraining the Market for Systemic Lupus Erythematosus?
      • Drug-Class-Specific Trends
        • Antimalarials
        • Corticosteroids
        • Immunosuppressants / Cytotoxic Drugs
        • B-Cell Modulators
        • Interferon-Alpha Inhibitors
        • Interleukin-12/23 Inhibitors
        • Jak Inhibitors
      • Alternative Market Scenarios
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
        • Clinical Manifestations
        • Disease Severity
        • Pathogenesis
      • Key Pathways and Drug Targets
        • B Cells
        • T Cells
        • Tissue Damage
        • Abnormal Cytokine and Chemokine Expression
    • Epidemiology
      • Key Findings
        • Key Updates
      • Epidemiology Populations
        • Diagnosed Prevalent Cases
        • Subpopulations
        • Drug-Treated Cases of Systemic Lupus Erythematosus
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Antimalarials
        • Corticosteroids
        • Immunosuppressants and Cytotoxics
        • B-Cell Modulators
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Systemic Lupus Erythematosus
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • IL-12 / 23 Inhibitors
        • Jak Inhibitors
        • Interferon-Alpha Inhibitors
        • Calcineurin Inhibitors
        • B-Cell Modulators
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Systemic Lupus Erythematosus Bibliography

Author(s): Ajay Puri, MBA; Sunali D. Goonesekera, SM

Ajay Puri is a Research Associate on the Immune and Inflammatory team at Decision Resources Group. He currently focuses on Inflammatory bowel disease (IBD). He holds a bachelor’s degree in Pharmacy and has earned his MBA in Pharmaceutical marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Business Research Associate (Oncology) at ZS Associates. He has worked on multiple client projects revolving around competitive intelligence, opportunity assessment, trend analysis, clinical trial analysis, and product/company profiling.  

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Systemic Lupus Erythematosus | Unmet Need | Detailed, Expanded Analysis: Lupus Nephritis

MARKET OUTLOOK Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (

View Details

Systemic Lupus Erythematosus | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay of treatment for systemic lupus erythematosus (SLE), a...

View Details